Ajanta Pharma, today announced the receipt of final approval for Voriconazole Tablets (50mg & 200mg), from the U.S. Food and Drug Administration (FDA). Voriconazole is a triazole antifungal for treatment of serious invasive fungal infections and the generic version of Vfend1.

Voriconazole tablets is part of ever-growing portfolio of products that Ajanta has developed for the U.S. market.

Shares of the company declined Rs 2.35, or 0.16%, to trade at Rs 1,472.00.

The total volume of shares traded was 9,603 at the BSE (11.34 a.m., Thursday).